Date: 2011-09-27
Type of information: Production agreement
Compound: adult stem cell products
Company: Lonza (Switzerland) Mesoblast (Australia)
Therapeutic area: Regenerative medicine
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: Global regenerative medicine company Mesoblast and Lonza Group have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products.The alliance will provide Mesoblast with significant commercial advantages, including certainty of capacity to meet long-term global supply of its proprietary Mesenchymal Precursor Cell (MPC) products. Under the agreement, Lonza will supply Mesoblast’s clinical and long-term commercial MPC product needs globally. Mesoblast also can trigger a process requiring Lonza to construct a purpose-built manufacturing facility exclusively for Mesoblast’s marketed products. In return, Mesoblast will purchase agreed quantities of marketed products from the facility. Mesoblast can exercise its right to buy out this manufacturing facility at a pre-agreed purchase price two years after the facility receives regulatory approval. Mesoblast will have exclusive access to Lonza’s Cell Therapy facilities in Singapore for the manufacture of allogeneic cell therapy products, subject to certain exceptions. Lonza will utilize its proprietary intellectual property to facilitate reductions in Mesoblast’s manufacturing costs and help enable development of enhanced second generation products.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
